全球動脈粥狀硬化斑塊切除術器械市場：市場規模、佔有率和趨勢分析（2025-2032 年）

全球動脈粥狀硬化斑塊切除術器械市場報告

2025年全球動脈粥狀硬化斑塊切除術器械市場規模為9.15億美元。在預測期內，該市場預計將以1.3%的複合年成長率成長，到2032年將達到約10億美元。

• 這份關於全球動脈粥狀硬化斑塊切除術器械市場的綜合報告涵蓋七個區域：北美、拉丁美洲、西歐、中東歐、中東、亞太地區和非洲。報告針對每個區域提供市場規模、銷售分析和平均售價數據，並預測至2032年，從而詳細展望市場未來的發展趨勢。與附件範例一樣，該報告結構清晰，易於操作，從市場規模分析入手，逐步深入到成長要素、限制因素、市場細分、競爭格局和策略應用案例。

本報告聚焦於全球動脈動脈粥狀硬化斑塊切除術市場，並對雷射動脈動脈粥狀硬化斑塊切除術器械和機械動脈粥狀硬化斑塊切除術切除用拋棄式產品進行了詳細分析。報告量化呈現了各細分市場的銷售量、手術量、平均售價、市場總值、市場佔有率、成長趨勢和預測。此外，報告還分析了近期併購、公司概況、產品系列和主要競爭對手。

整體而言，動脈粥狀硬化斑塊切除術器械市場在臨床和策略上都佔據著重要地位，但它並非高成長、大規模生產的品類。相反，它是一個利基市場，由那些將斑塊改良作為複雜病例、特定病變類型以及更廣泛的血管內治療策略一部分的醫生所驅動。

市場概覽

全球動脈粥狀硬化斑塊切除術器械市場涵蓋用於在血管內治療過程中清除周邊血管斑塊的器械。與透過機械擴張來拓寬血管的標準球囊血管成形術不同，動脈粥狀硬化斑塊切除術能夠主動清除或減重病變。這可以改善管腔通暢度，降低斑塊負荷，並為後續治療（例如球囊血管成形術或藥物釋放型球囊）做好準備。

動脈粥狀硬化斑塊切除術適用於多種周邊血管疾病，尤其適用於鈣化、病灶複雜或血管尺寸較大而導致單純球囊擴張治療效果不佳的情況。這包括膝上和膝下血管手術。由於斑塊清除可以改善血管通暢性，動脈粥狀硬化斑塊切除術已成為許多醫生治療複雜周邊動脈疾病的重要手段。

該市場的一個關鍵趨勢是向微創和精準介入治療的轉變。新型動脈粥狀硬化斑塊切除術系統在設計上改進了導航控制，增強了斑塊清除能力，並與影像引導下的自主手術高度相容。這支持了更廣泛的臨床趨勢，即採用更具針對性的血管內解決方案，以減少開放性手術，旨在提高治療效果並減輕手術負擔。

然而，這仍然是一個高度專業化的市場。動脈粥狀硬化斑塊切除術器械比許多標準血管內器械更昂貴，其額外的成本和技術要求通常僅限於臨床複雜程度較高的手術。因此，儘管市場規模保持在一定水平，但與大規模的血管治療領域相比，其成長相對受限。

市場促進因素

支架置入術的過渡趨勢

全球動脈粥狀硬化斑塊切除術器械市場最重要的促進因素之一是某些周邊血管手術中常規支架置入術的減少。對於某些類型的病變，特別是短距離病變，醫生通常更傾向於斑塊動脈粥狀硬化斑塊切除術聯合球囊血管成形術，而不是永久性支架置入術。這種方法可以為未來的治療選擇保留更多可能性，並且在不適合植入植入的情況下，有助於維持良好的長期血管通暢率。

這種轉變意義重大，因為它改變了斑塊切除術的角色，使其從一種針對特定病變的動脈粥狀硬化斑塊切除術轉變為血管準備和病變特異性治療中更為重要的組成部分。隨著越來越多的醫生將動脈粥狀硬化斑塊切除術納入治療流程，其設備需求將直接受益。臨床數據也支持聯合治療的必要性。例如，DEFINITIVE AR試驗的結果表明，定向斑塊動脈粥狀硬化斑塊切除術合併藥物釋放型球囊可提高長病變和嚴重鈣化病變的通暢率。即使由於對紫杉醇的擔憂，藥物釋放型球囊的使用有所改變，但血管準備的常規做法仍在繼續推動動脈粥狀硬化斑塊切除術的應用。

血管支架再狹窄率高

支架置入術後較高的血管再阻塞率是另一個主要的成長要素。血管再阻塞仍然是周邊血管介入治療中常見的臨床問題，而當發生血管再阻塞時，動脈粥狀硬化斑塊切除術是重新開通血管的首選方法之一。因此，動脈粥狀硬化斑塊切除術不僅在初次介入治療中發揮重要作用，在再次治療中也是如此。

對於希望減少單純球囊擴張術所致血管損傷的醫師而言，動脈粥狀硬化斑塊切除術也具有潛在益處。在某些手術中，球囊擴張術可能導致血管撕裂，從而在血管癒合過程中增加血管再阻塞。斑塊切除動脈粥狀硬化斑塊切除術通過去除斑塊而非僅依賴球囊擴張力，在以最大限度減少血管損傷為首要目標的手術中，可作為一種替代或輔助手段。

糖尿病患者膝下手術數量增加

膝下（BTK）手術是動脈粥狀硬化斑塊切除術器械市場中一個特別重要的成長要素。 2022年，約35%的動脈粥狀硬化斑塊切除術手術是在膝下進行的，這反映了該手術在小血管介入治療中的重要性。由於膝下手術中支架置入的可能性低於膝上手術，因此動脈粥狀硬化斑塊切除術在這些手術中發揮更關鍵的作用。

這一趨勢與糖尿病患者人數的增加密切相關。糖尿病患者易患遠端周邊血管疾病，需對膝下血管進行治療。隨著糖尿病患者群體不斷成長和老化，膝下血管介入治療的需求預計將會增加。因此，動脈粥狀硬化斑塊切除術有望繼續發揮其臨床作用，尤其是在支架置入不可行且斑塊清除尤為有益的病變類型。

市場限制

缺乏保險報銷

動脈粥狀硬化斑塊切除術器械市場面臨的最大阻礙因素是保險報銷不足，尤其是在歐洲。動脈粥狀硬化斑塊切除術器械價格昂貴，在許多醫療體系中，保險無法充分涵蓋其常規使用費用。因此，醫生和醫院在考慮動脈粥狀硬化斑塊切除術之前，往往會先探索成本較低的替代方案。

這項報銷問題至關重要，因為動脈粥狀硬化斑塊切除術並非孤立存在。它與球囊血管成形術、藥物釋放型球囊和支架等其他治療方法動脈粥狀硬化斑塊切除術，在某些情況下，這些方法可能更具經濟效益。隨著報銷與臨床療效的關聯日益緊密，動脈粥狀硬化斑塊切除術不僅要在技術層面，更要在經濟效益方面參與競爭。

動脈損傷與醫師的猶豫

動脈損傷也是市場上的重要限制因素。機械式動脈粥狀硬化斑塊切除術裝置由於其旋轉和切割動作可能導致血管撕裂，而雷射裝置如果能量超過斑塊面積，則可能損傷血管壁。這些風險使得醫生們持謹慎態度，並在某些醫療環境中限制了這些裝置的使用。

在許多情況下，如果醫生認為某種更簡單、更熟悉的治療方法足以治療病變，他們可能會選擇這種治療方法。這使得動脈粥狀硬化斑塊切除術的應用僅限於具有明確臨床價值的治療方法。儘管影像技術的進步和器械設計的精準化增強了醫生的信心，但人們對該手術複雜性和風險的認知仍然阻礙了其廣泛應用。

與替代治療方法的激烈競爭

動脈粥狀硬化斑塊切除術也面臨來自其他幾種血管內治療方法的競爭。藥物釋放型球囊、標準球囊血管成形術和支架置入術都是成熟的治療選擇，醫生可以根據病變類型、解剖結構、保險覆蓋範圍以及自身經驗進行選擇。在許多情況下，動脈粥狀硬化斑塊切除術並非預設選項，而是一種可選方案。

這種競爭壓力可能會限制目標市場，尤其是在替代療法在經濟或操作上更具優勢的情況下。即使動脈粥狀硬化斑塊切除術具有技術優勢，也必須權衡這些優勢與成本、訓練和手術流程之間的關係。

市場覆蓋範圍和數據範圍

定量範圍

市場規模、市佔率、市場預測、市場成長率、銷售量、平均售價。

定性範圍

市場促進因素和阻礙因素、市場規模和成長趨勢、近期併購、公司簡介、產品系列和主要競爭對手。

目標期

基準年：2025 年，歷史資料：截至 2022 年，預測：截至 2032 年。

按地區定位

北美洲、拉丁美洲、西歐、中歐和東歐、中東、亞太地區、非洲。

包含的資料類型

銷售量、平均售價、治療次數、市場規模和成長趨勢。

本報告提供定量和定性分析，幫助使用者了解治療模式、定價、競爭對手趨勢和臨床實踐如何塑造各地區的動脈粥狀硬化動脈粥狀硬化斑塊切除術設備市場。

目標市場及區隔

• 本報告涵蓋全球動脈粥狀硬化斑塊切除術器械市場，並進一步細分為以下幾個部分：

雷射動脈動脈粥狀硬化斑塊切除術裝置

此部分內容包括用於透過可控能量輸出切除斑塊的雷射系統。這些設備對於某些類型的病變以及醫生需要精準治療軟斑塊和鈣化物質的情況尤其有用。

機械動脈粥狀硬化斑塊切除術切除術用拋棄式產品

該細分市場包括一次性動脈動脈粥狀硬化斑塊切除術裝置，這些裝置透過切割、拋光或旋轉運動機械地去除斑塊。這些產品廣泛應用於各種周邊血管治療，目前仍佔據著較大且穩定的市場佔有率。

根據銷售量、平均售價和市場總值對每個細分市場進行分析，預測期至 2032 年，歷史數據截至 2022 年。

競爭分析

2024年，雅培血管是周邊血管動脈粥狀硬化斑塊切除術術器械市場的領先競爭者。 2023年4月收購心血管系統公司（Cardiovascular Systems, Inc.）進一步鞏固了其市場地位，此次收購為其產品組合新增了Diamondback 360和Stealth 360周邊血管動脈粥狀硬化斑塊切除術系統。 Diamondback 360是一款傳統的旋轉系統，其設計旨在減少手術併發症，例如血管再阻塞和血管穿孔。該平台已核准用於膝上和膝下手術，尤其在膝下手術領域廣泛應用。其單次手術器械使用率高於平均水平，這也是其獲利能力的另一個優勢。

美敦力仍然是全球動脈粥狀硬化斑塊切除術市場中最成熟的競爭者之一。多年來，該公司透過收購Covidien和ev3等公司不斷鞏固其市場地位。這些收購使美敦力獲得了SilverHawk系列產品，隨後又透過HawkOne和TurboHawk進一步豐富了其產品組合。 SilverHawk採用旋轉刀片式刮除器，能夠清除大血管中的大量斑塊，尤其適用於大腿以上的手術，從而建立了強大的市場基礎。隨後，產品系列的開發擴展到了小腿應用領域。在美敦力2025年的銷售預測中，HawkOne預計將引領醫院市場，其次是TurboHawk。同時，SilverHawk仍保持著該系列產品中價格較低的優勢。

飛利浦是雷射動脈粥狀硬化斑塊切除術領域的主要企業，其2017年收購Spectranetics公司進一步鞏固了這一地位。此次收購在其現有的CVX-300準分子雷射和斑塊雷射系統基礎上，新增了Turbo導管產品線。 Turbo-Elite是其最暢銷的產品，而Turbo-Power預計到2025年將貢獻高價銷售。結合更廣泛的病變管理策略，飛利浦在能夠處理軟斑塊的雷射系統方面擁有明顯的競爭優勢。此外，門診檢查室的成長也使該公司受益匪淺。然而，CVX-300準分子雷射的平均售價較高，這意味著許多醫療機構選擇租賃而非直接購買，這阻礙了其廣泛應用，儘管該設備具有卓越的臨床性能。

總體而言，競爭格局是由透過收購擴大產品組合、特異性病變的能力以及在機械和雷射動脈動脈粥狀硬化斑塊切除術工作流程中支援醫生的能力所塑造的。

科技和醫療治療的發展趨勢

動脈粥狀硬化斑塊切除術市場最顯著的趨勢之一是向微創和精準介入治療的轉變。新型系統設計改​​進了導航控制，提高了斑塊清除效率，從而鞏固了動脈粥狀硬化斑塊切除術的地位，使其不僅是支架置入術的替代方案，而且成為一種靶向病變形成治療手段。

即時影像引導的重要性也日益凸顯。影像品質的提升使醫生能夠更準確地評估斑塊負荷、病變形態和治療終點，從而實現更具選擇性和更精準的動脈粥狀硬化斑塊切除術。

另一個重要趨勢是動脈粥狀硬化斑塊切除術在聯合治療的應用日益廣泛。醫生不再單獨使用動脈粥狀硬化斑塊切除術，而是擴大將其與球囊血管成形術和其他輔助療法相結合，以最佳化鈣化或複雜病變的治療效果。

隨著糖尿病盛行率的上升，醫生開始探索微血管系統中支架置入術的替代方案，膝下介入治療仍是研究的重點領域。這推動了更適用於遠端解剖結構的器材的持續創新。

地區

本報告提供了涵蓋北美、歐洲、亞太地區、拉丁美洲以及中東和非洲的全球研究成果。

一份長達 61 頁的詳細市場分析、市場區隔和預測數據報告。

附錄：調查方法和縮寫詞彙表。

這份報告的意義

到 2032 年，全球動脈粥狀硬化斑塊切除術器械市場中最具發展潛力的機會在哪裡？

從支架置入術過渡到血管內治療，對複雜鈣化病變的動脈動脈粥狀硬化斑塊切除術的需求有何影響？

膝下手術數量的增加和糖尿病患者數量的增加將在長期銷售成長中發揮什麼作用？

報銷限制和程序風險如何影響區域採用率？

機械和雷射動脈粥狀硬化斑塊切除術領域的主要企業有哪些？收購如何改變了競爭格局？

在這個臨床上非常重要的、成長緩慢的類別中，定價、治療結構和病變複雜性如何影響市場價值？

iData Research 的《全球動脈動脈粥狀硬化斑塊切除術器械市場報告》透過詳細的市場區隔、競爭分析、定價數據和市場預測，解答了這些問題。利用這份報告，您可以比較和評估競爭對手，了解手術需求，並在周邊血管器械這一專業且關鍵的領域制定策略。

目錄

圖表清單

調查方法

• 第一步：計劃啟動與團隊組建
• 步驟 2：準備資料系統並進行二次調查。
• 步驟 3：設計和準備訪談和調查問卷。
• 第四步：進行初步調查
• 第五步：調查與分析：建立基準估計值
• 第六步：市場預測與分析
• 步驟 7：辨識策略機遇
• 步驟 8：最終審核和市場推廣
• 步驟九：客戶回饋與市場監測

全球關稅的影響

動脈粥狀硬化斑塊切除術器械市場

• 執行摘要
  • 全球動脈粥狀硬化斑塊切除術器械市場概覽
  • 競爭分析
  • 目標程式
  • 目標市場
  • 目標區域
• 介紹
• 手術次數
• 市場概覽
  • 按細分市場
  • 按地區
• 市場分析與預測
  • 雷射動脈動脈粥狀硬化斑塊切除術設備市場
  • 機械動脈動脈粥狀硬化斑塊切除術裝置市場
• 促進因素和抑制因素
• 競爭性市佔率分析

簡稱

Global Atherectomy Device Market Report

The global atherectomy device market was valued at $915 million in 2025. Over the forecast period, the market is expected to grow at a CAGR of 1.3% to reach approximately $1.0 billion by 2032.

• The full report suite on the global market for atherectomy devices covers seven geographical regions: North America, Latin America, Western Europe, Central and Eastern Europe, the Middle East, Asia-Pacific and Africa. For each region, the report provides market valuation, unit analysis and average selling price data, while also extending projections through 2032 to provide a detailed view of how the market is expected to develop over time. As with the attached example, this report is structured to move from market sizing into drivers, limiters, segmentation, competition and strategic use cases in a clear and practical format .

This report focuses on the global market for atherectomy devices and includes detailed analysis of laser atherectomy devices and mechanical atherectomy disposables. Across these segments, the report quantifies unit sales, procedure numbers, average selling prices, total market value, market shares, growth trends and forecasts. It also includes recent mergers and acquisitions, company profiles, product portfolios and analysis of leading competitors.

Overall, the atherectomy device market remains clinically important and strategically relevant, but it is not a high-growth mass-volume category. Instead, it is a focused market driven by complex cases, specific lesion types and physicians who value plaque modification as part of a broader endovascular treatment strategy.

Market Overview

The global atherectomy device market includes devices used to remove plaque from peripheral blood vessels during endovascular procedures. Unlike standard balloon angioplasty, which expands the vessel through mechanical dilation, atherectomy actively removes or debulks the lesion. This can improve luminal gain, reduce plaque burden and prepare the vessel for additional treatment, such as balloon angioplasty or drug-coated balloon use.

Atherectomy is used across a range of peripheral vascular applications, but it is especially relevant in cases where calcification, lesion complexity or vessel size make standard balloon-only treatment less effective. This includes both above-the-knee and below-the-knee procedures. Because plaque removal can improve vessel preparation, atherectomy has become an important part of treatment planning for many physicians managing more difficult peripheral arterial disease cases.

A major trend in this market is the shift toward minimally invasive and precision-based intervention. Newer atherectomy systems are being designed with better navigational control, improved plaque removal capability and stronger compatibility with imaging-guided procedures. This supports the broader clinical movement away from open surgery and toward more targeted intravascular solutions that aim to improve outcomes while reducing procedural trauma.

Still, this remains a specialized market. Atherectomy devices are more expensive than many standard endovascular tools, and they are often reserved for procedures where clinical complexity justifies the added cost and technique. This keeps the market meaningful, but relatively restrained in growth compared with larger vascular categories.

Market Drivers

Trend Away from Stenting

One of the most important drivers in the global atherectomy device market is the trend away from routine stenting in selected peripheral procedures. In certain lesion types, especially short lesions, physicians often prefer atherectomy combined with balloon angioplasty over placing a permanent stent. This approach can preserve future treatment options and may support good long-term patency in cases where leaving an implant is not ideal.

This shift is especially important because it changes the role of atherectomy from a niche debulking tool into a more deliberate part of vessel preparation and lesion-specific therapy. As more physicians integrate atherectomy into their treatment algorithms, unit demand benefits directly. Interest in combination therapy has also been supported by clinical data, including results from the DEFINITIVE AR study, which showed that combining directional atherectomy with drug-coated balloons improved patency in long lesions and in lesions with severe calcification. Even with changes in drug-coated balloon usage after paclitaxel concerns, the broader practice of vessel preparation continues to support atherectomy adoption.

High Stent Restenosis Rates

High rates of restenosis after stent placement are another major growth driver. Restenosis remains a common clinical problem in peripheral vascular intervention, and when it occurs, atherectomy is one of the preferred ways to reopen the vessel. This makes atherectomy relevant not only in first-time intervention, but also in repeat procedures.

Atherectomy also offers a potential advantage in cases where physicians want to reduce the vessel trauma associated with balloon dilation alone. In some procedures, balloon expansion can create dissections that contribute to the restenosis process as the vessel heals. By removing plaque rather than relying only on balloon force, atherectomy can serve as an alternative or adjunct in procedures where reducing vessel injury is a priority.

Growth in BTK Procedures in Diabetic Patients

Below-the-knee procedures are an especially important driver for the atherectomy device market. In 2022, about 35% of atherectomy procedures were performed below the knee, reflecting how relevant this category is in smaller-vessel intervention. Because stents are less likely to be placed below the knee than above the knee, atherectomy plays a more important role in these procedures.

This trend is closely linked to the rising diabetic population. Diabetic patients are more likely to develop the kind of distal peripheral disease that requires below-the-knee treatment. As this patient base grows and ages, the need for BTK intervention is expected to rise as well. That gives atherectomy a durable clinical role, especially in lesion sets where stenting is less practical and plaque modification is particularly useful.

Market Limiters

Lack of Reimbursement

The largest limiter for the atherectomy device market is lack of reimbursement, particularly in Europe. Atherectomy devices are expensive, and in many healthcare systems reimbursement does not fully support their routine use. This means physicians and hospitals often exhaust lower-cost alternatives before turning to atherectomy.

This reimbursement issue matters because atherectomy does not compete in a vacuum. It sits alongside balloon angioplasty, drug-eluting balloons and stents, all of which may be perceived as more economically practical in certain settings. As reimbursement becomes more closely tied to demonstrated clinical outcomes, atherectomy must compete not only on technical performance, but also on economic justification.

Arterial Damage and Physician Hesitation

Arterial damage is another important market limiter. Mechanical atherectomy devices can cause dissections because of their rotating and cutting action, while laser devices can occasionally damage the vessel wall if energy extends beyond the plaque. These risks have contributed to caution among physicians and have limited adoption in some settings.

In many cases, physicians may choose simpler or more familiar treatment methods if they believe those options are adequate for the lesion. This limits atherectomy use to procedures where its clinical value is clear. Although better imaging and more precise device design are improving physician confidence, the category still carries a perception of procedural complexity and risk that can limit broader adoption.

Strong Competition from Alternative Treatment Options

Atherectomy also faces competition from multiple other endovascular therapies. Drug-eluting balloons, standard balloon angioplasty and stenting all remain well-established options, and physicians can choose among them depending on lesion type, anatomy, reimbursement and personal experience. In many procedures, atherectomy is not the default option, but rather a selective one.

This competitive pressure limits the addressable market, particularly when alternative therapies are easier to justify economically or operationally. Even when atherectomy offers technical advantages, those benefits must be weighed against cost, training and procedural workflow.

Market Coverage and Data Scope

Quantitative Coverage

Market size, market shares, market forecasts, market growth rates, units sold and average selling prices.

Qualitative Coverage

Market drivers and limiters, market size and growth trends, recent mergers and acquisitions, company profiles, product portfolios and leading competitors.

Time Frame

Base year 2025, historical data to 2022 and forecasts through 2032.

Regional Coverage

North America, Latin America, Western Europe, Central and Eastern Europe, the Middle East, Asia-Pacific and Africa.

Data Types Included

Unit sales, average selling prices, procedure numbers, market size and growth trends.

This report provides both quantitative and qualitative analysis, helping users understand how procedure patterns, pricing, competitive movement and clinical practice are shaping the atherectomy device market across regions.

Markets Covered and Segmentation

• The report covers the Global Atherectomy Device Market, further segmented into:

Laser Atherectomy Devices

This segment includes laser-based systems used to ablate plaque with controlled energy delivery. These devices are particularly relevant in selected lesion types and in settings where physicians value the ability to address both soft plaque and calcified material with precision.

Mechanical Atherectomy Disposables

This segment includes disposable atherectomy devices that mechanically remove plaque through cutting, sanding or rotational action. These products are used across a range of peripheral procedures and remain the larger and more established portion of the market.

Each segment is analyzed by unit sales, average selling prices and total market value, with forecasts through 2032 and historical context to 2022.

Competitive Analysis

Abbott Vascular was the leading competitor in the peripheral atherectomy device market in 2024. Its position was strengthened by the April 2023 acquisition of Cardiovascular Systems, Inc., which added the Diamondback 360 and Stealth 360 peripheral atherectomy systems to its portfolio. Diamondback 360, a traditional rotational system, incorporates design features intended to reduce procedural side effects such as restenosis and vessel perforation. The platform is approved for both above-the-knee and below-the-knee procedures and has particularly strong adoption in the below-the-knee segment. It also benefits from higher-than-average device usage per procedure, which supports revenue strength.

Medtronic remains one of the most established competitors in the global atherectomy market. Its presence was built over time through acquisitions, including Covidien and ev3, and those transactions gave the company access to the SilverHawk line and later portfolio improvements such as HawkOne and TurboHawk. SilverHawk established a strong market foundation by using rotating blade shavers capable of removing significant plaque burden in larger vessels, especially in above-the-knee procedures. Over time, portfolio development extended into below-the-knee applications. In Medtronic's 2025 revenue mix, HawkOne led in the hospital market, followed by TurboHawk, while SilverHawk remained the lower-cost option within the family.

Philips is the leading player in laser atherectomy and built its position through the 2017 acquisition of Spectranetics. That deal added the CVX-300 Excimer and Nexcimer Laser System, along with the Turbo catheter portfolio. Turbo-Elite led in revenue performance, while Turbo-Power also contributed premium-priced sales in 2025. Philips has a distinct competitive advantage because its laser systems can address both soft plaque and calcium when combined with broader lesion management strategies. The company also benefited from growth in outpatient labs. However, the high average selling price of the CVX-300 Excimer has encouraged rental models rather than direct ownership in many accounts, which can limit wider adoption despite strong clinical capability.

Overall, the competitive landscape is shaped by acquisition-driven portfolio expansion, lesion-specific performance and the ability to support physicians across both mechanical and laser atherectomy workflows.

Technology and Practice Trends

One of the clearest trends in the atherectomy market is the move toward minimally invasive and precision-based intervention. Newer systems are being designed with better navigational control and more efficient plaque removal, which helps position atherectomy as a targeted lesion preparation tool rather than a blunt alternative to stenting.

Real-time imaging guidance is also becoming more important. As imaging quality improves, physicians are better able to identify plaque burden, lesion morphology and treatment endpoints. This supports more selective and more confident atherectomy use.

Another important trend is the growing use of atherectomy in combination procedures. Rather than using atherectomy alone, physicians increasingly pair it with balloon angioplasty and other adjunctive tools to optimize outcomes in calcified or complex lesions.

Below-the-knee intervention remains a major focus area as diabetic disease burden rises and physicians look for alternatives to stenting in smaller vessels. This supports continued innovation in devices suited for more distal anatomy.

Geography

This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.

61 pages of detailed market analysis, segmentation and forecast data.

Methodology Appendix and Acronym Glossary.

Why This Report

Where are the most meaningful opportunities in the global atherectomy device market through 2032?

How is the shift away from stenting influencing atherectomy demand in complex and calcified lesions?

What role do below-the-knee procedures and diabetic patient growth play in long-term unit expansion?

How do reimbursement limitations and procedural risk affect adoption across regions?

Which companies lead in mechanical and laser atherectomy, and how have acquisitions changed the competitive landscape?

How are pricing, procedure mix and lesion complexity shaping market value in a slow-growth but clinically important category?

The Global Atherectomy Device Market Report from iData Research answers these questions with detailed segmentation, competitive analysis, pricing data and market forecasting. Use it to benchmark competitors, understand procedural demand and support strategy in a specialized but important peripheral vascular device segment.

TABLE OF CONTENT

List Of Figures

List Of Charts

Research Methodology

• Step 1: Project Initiation & Team Selection
• Step 2: Prepare Data Systems And Perform Secondary Research
• Step 3: Preparation For Interviews & Questionnaire Design
• Step 4: Performing Primary Research
• Step 5: Research Analysis: Establishing Baseline Estimates
• Step 6: Market Forecast And Analysis
• Step 7: Identify Strategic Opportunities
• Step 8: Final Review And Market Release
• Step 9: Customer Feedback And Market Monitoring

Impact Of Global Tariffs

Atherectomy Device Market

• 7.1 Executive Summary
  • 7.1.1 Global Atherectomy Device Market Overview
  • 7.1.2 Competitive Analysis
  • 7.1.3 Procedures Included
  • 7.1.4 Markets Included
  • 7.1.5 Regions Included
• 7.2 Introduction
• 7.3 Procedure Numbers
• 7.4 Market Overview
  • 7.4.1 By Segment
  • 7.4.2 By Region
• 7.5 Market Analysis And Forecast
  • 7.5.1 Laser Atherectomy Device Market
  • 7.5.2 Mechanical Atherectomy Device Market
• 7.6 Drivers And Limiters
  • 7.6.1 Market Drivers
  • 7.6.2 Market Limiters
• 7.7 Competitive Market Share Analysis

Abbreviations

LIST OF CHARTS

• Chart 7-1: Atherectomy Device Market, Global, 2025 & 2032
• Chart 7-2: Atherectomy Procedures, Global, 2025
• Chart 7-3: Atherectomy Procedures by Region, Global, 2022 - 2032
• Chart 7-4: Atherectomy Device Market by Segment, Global, 2022 - 2032
• Chart 7-5: Atherectomy Device Market by Region, Global, 2022 - 2032
• Chart 7-6: Leading Competitors, Atherectomy Device Market, Global, 2025

LIST OF FIGURES

• Figure 7-1: Atherectomy Procedures Covered
• Figure 7-2: Atherectomy Markets Covered
• Figure 7-3: Atherectomy Device Regions Covered, Global (1 of 2)
• Figure 7-4: Atherectomy Device Regions Covered, Global (2 of 2)
• Figure 7-5: Atherectomy Procedures by Region, Global, 2022 - 2032
• Figure 7-6: Atherectomy Procedures by Country, North America, 2022 - 2032
• Figure 7-7: Atherectomy Procedures by Country, Latin America, 2022 - 2032 (1 of 2)
• Figure 7-8: Atherectomy Procedures by Country, Latin America, 2022 - 2032 (2 of 2)
• Figure 7-9: Atherectomy Procedures by Country, Western Europe, 2022 - 2032
• Figure 7-10: Atherectomy Procedures by Country, Central & Eastern Europe, 2022 - 2032 (1 of 2)
• Figure 7-11: Atherectomy Procedures by Country, Central & Eastern Europe, 2022 - 2032 (2 of 2)
• Figure 7-12: Atherectomy Procedures by Country, Middle East, 2022 - 2032
• Figure 7-13: Atherectomy Procedures by Country, Asia-Pacific, 2022 - 2032 (1 of 3)
• Figure 7-14: Atherectomy Procedures by Country, Asia-Pacific, 2022 - 2032 (2 of 3)
• Figure 7-15: Atherectomy Procedures by Country, Asia-Pacific, 2022 - 2032 (3 of 3)
• Figure 7-16: Atherectomy Procedures by Country, Africa, 2022 - 2032
• Figure 7-17: Atherectomy Device Market by Segment, Global, 2022 - 2032 (US$M)
• Figure 7-18: Atherectomy Device Market by Region, Global, 2022 - 2032 (US$M)
• Figure 7-19: Laser Atherectomy Device Market, Global, 2022 - 2032
• Figure 7-20: Units Sold by Region, Laser Atherectomy Device Market, Global, 2022 - 2032
• Figure 7-21: Average Selling Price by Region, Laser atherectomy Device Market, Global, 2022 - 2032 (US$)
• Figure 7-22: Market Value by Region, Laser Atherectomy Device Market, Global, 2022 - 2032 (US$M)
• Figure 7-23: Mechanical Atherectomy Device Market, Global, 2022 - 2032
• Figure 7-24: Units Sold by Region, Mechanical Atherectomy Device Market, Global, 2022 - 2032
• Figure 7-25: Average Selling Price by Region, Mechanical Atherectomy Device Market, Global, 2022 - 2032 (US$)
• Figure 7-26: Market Value by Region, Mechanical Atherectomy Market, Global, 2022 - 2032 (US$M)
• Figure 7-27: Leading Competitors, Atherectomy Device Market, Global, 2025